PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsCanadian regulators grant world's first approval for a stem cell drug

BioNews

Canadian regulators grant world's first approval for a stem cell drug

Published 28 February 2013 posted in News and appears in BioNews 657

Author

Vicki Kay

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).

The world's first stem cell drug has been approved by Canadian authorities. US biotech company, Osiris Therapeutics, has been given the go-ahead to market its drug, Prochymal, for the treatment of graft-versus-host-disease (GvHD) in children who fail to respond to steroids....

The world's first stem cell drug has been approved by Canadian authorities. US biotech company, Osiris Therapeutics, has been given the go-ahead to market its drug, Prochymal, for the treatment of graft-versus-host-disease (GvHD) in children who fail to respond to steroids.

Although stem cell transplants are currently used in a number of medical procedures, Prochymal is the first regulatory approved stem cell product to be manufactured and sold by a drug company. It marks a major step forward for the field of regenerative medicine.

'It's really a good day for the concept and the hope behind stem cell therapies becoming a reality', said Dr Randal Mills, the chief executive of Osiris.

GvHD is a complication that can occur following bone marrow transplantation and happens when immune cells in the donated bone marrow start attacking the recipient's organs. GvHD can cause severe damage to the skin, liver and digestive tract and is fatal in up to 80 percent of children affected. Treatment with steroids can help to manage symptoms, but often proves ineffective.

Prochymal is a preparation of mesenchymal stem cells extracted from the bone marrow of young adult donors. It is unclear exactly how the drug works, but clinical trial data has shown that Prochymal is effective in a specific subset of patients. Sixty percent of children with severe cases of GvHD who had not previously responded to steroid treatment showed clinically significant improvement, prompting Canadian authorities to approve the drug for use in this category.

Lead investigator Dr Joanne Kurtzberg, who heads the Pediatric Bone Marrow Transplant Program at Duke University, USA said: 'I have personally seen Prochymal reverse the debilitating effects of severe GvHD in many of my patients and now, after nearly two decades of research, the data demonstrating consistently high response rates, a strong safety profile and improved survival clearly support the use of Prochymal in the management of refractory GvHD'.

The announcement is a positive boost for Prochymal, whose future had looked uncertain. In 2009, two late-stage clinical trials failed to find any difference between Prochymal and a placebo in the treatment of GvHD. Attempts to trial Prochymal as a treatment for illnesses including Crohn's disease and diabetes had also resulted in several failures. In February this year, French pharmaceutical company Sanofi, who held the rights to sell Prochymal outside of North America, announced that it was stopping work on the drug.

Approval was granted upon the condition that testing continues once the drug goes to market. The US Food and Drug Administration has stated it will not consider approving the drug in the USA without further data.

'While today marks the first approval of a stem cell drug, now that the door has been opened, it will surely not be the last', said Dr Mills.

The drug will be commercially available in Canada later this year.

Related Articles

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
28 February 2013 • 2 minutes read

Growth factor from stem cells spurs MS recovery in mice

by Dr Lux Fatimathas

A chemical produced by stem cells promotes recovery in mice with the autoimmune neurological disease, multiple sclerosis. Hepatocyte growth factor, which is produced by human mesenchymal stem cells, appeared to both repair existing damage and prevent future neurological harm in a mouse model of the disease...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
13 February 2013 • 2 minutes read

Stem cell treatment counters kidney rejection in early trial

by Dr Rebecca Robey

Stem cell therapy may remove the need for organ transplant recipients to have lifelong drug treatment to combat the risk of rejection, which would dramatically improve patients' quality of life...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
23 January 2013 • 1 minute read

Disappointing results one year into diabetes stem cell trial

by Marianne Kennedy

Biotech company Osiris Therapeutics has this month released an optimistic update on its Phase II trial evaluating the use of adult stem cells for the treatment of type 1 diabetes, despite lacking positive results...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
12 December 2012 • 2 minutes read

Stem cell therapy hope for kidney transplant patients

by George Frodsham

Scientists have found a new method of suppressing the automatic rejection of donated kidneys in transplant patients, by using the donor's stem cells. In a small trial carried out at Stanford University, California, eight out of 12 patients were able to stop taking anti-rejection drugs, which are usually a lifelong necessity, following this treatment....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
2 November 2012 • 2 minutes read

Gene therapy approved in Europe for first time

by Dr Lucy Spain

The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat a rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved for the Western market and offers the first therapeutic treatment for people with LPLD....

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
9 June 2009 • 1 minute read

Stem cells surprise scientists

by BioNews

Scientists in the US and Canada have discovered a particular type of bone marrow stem cell that does not cause rejection when transplanted. The scientists have found that, unlike most stem cells transplanted from one person to another, these cells, taken from the bone marrow of adults, do not trigger...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Private equity firm invests in successful London IVF clinic

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856